Tenjarla Srini 4

What Happened

• Tenjarla Srini, Serina Therapeutics' Senior VP, CMC & Formulation, was granted a derivative award covering 69,000 shares on 2026-02-03. The reported acquisition price is $0.00 (the filing lists this as an award/derivative, not an open-market buy).
• This is an equity award/option-style grant — no cash cost or sale occurred at grant, and no immediate shares were sold.

Key Details

• Transaction date: 2026-02-03; SEC Form 4 filed: 2026-02-17.
• Transaction type/code: A (award/grant of a derivative security).
• Shares/amount: 69,000 shares granted; reported price $0.00 (reflects an award/option).
• Shares owned after transaction: Not specified in the data provided in this summary.
• Footnote (vesting): The award vests 12/48ths after 12 months from the vesting start date, then 1/48th each month thereafter until fully vested (4-year schedule).
• Timeliness: Filing posted 14 days after the transaction date — appears late relative to the SEC’s typical 2-business-day Section 16 reporting requirement.

Context

• This is an equity award (derivative grant) used for compensation and does not necessarily signal immediate buying or selling by the insider. Unlike open-market purchases, grants are routine executive compensation; purchases or sales are generally more directly informative about an insider’s market view.
• The vesting schedule means Srini must stay with the company for the specified periods before shares become exercisable or transferable.